Opinion|Videos|December 12, 2025
Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis
It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!
Advertisement
Episodes in this series
Deucravacitinib, approved in 2022, was the first selective TYK2 inhibitor for moderate-to-severe psoriasis. Can you describe its mechanism of action?
What are your impressions of the recently published long-term data for deucravacitinib in plaque psoriasis, which demonstrated sustained efficacy and a consistent safety profile through five years of treatment?
How does this data influence your perception of its role in long-term disease management?
Which patients are ideal candidates for deucravacitinib?
Advertisement
Related to this article
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
Anaphylm Is Back at the FDA: A Clinician FAQ on Needle-Free Epinephrine
5